A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer
NCT ID: NCT03800134
Last Updated: 2025-06-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE3
825 participants
INTERVENTIONAL
2018-12-06
2028-09-11
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Durvalumab Following Radiation Therapy in Patients With Stage 3 Unresectable NSCLC Ineligible for Chemotherapy
NCT04249362
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
NCT05211895
Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer
NCT03519971
Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy.
NCT04642469
A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
NCT05221840
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm 1: Durvalumab with platinum-based chemotherapy
Patients will receive durvalumab 1500 mg in combination with platinum-based chemotherapy every 3 weeks for up to 4 cycles prior to surgery, followed by durvalumab 1500 mg monotherapy every 4 weeks for up to 12 cycles after surgery unless disease is deemed unresectable, disease recurrence, or unacceptable toxicity
The platinum-based chemotherapy will be based on tumour histology and Investigator discretion:
* cisplatin with pemetrexed
* carboplatin with pemetrexed
* carboplatin with paclitaxel
* cisplatin with gemcitabine (or carboplatin with gemcitabine for patients who have comorbidities or who are unable to tolerate cisplatin per the investigator's judgment)
Durvalumab
1500mg on Day 1 of each 3-week cycle for 4 cycles during the neoadjuvant period and 1500mg on Day 1 of each 4-week cycle for 12 cycles during the adjuvant period
Carboplatin
Area under the curve of 5/6 on Day 1 of each 3-week cycle for 4 cycles
Cisplatin
75 mg/m2 on Day 1 of each 3-week cycle, for 4 cycles
Pemetrexed
500 mg/m2 on Day 1 of each 3-week cycle for 4 cycles.
Paclitaxel
200mg/m2 on Day 1 of each 3-week cycle for 4 cycles.
Gemcitabine
1250 mg/m2 on Day 1 and Day 8 of each 3-week cycle, for 4 cycles.
Surgery
Expected within 40 days from the last dose of Investigational Product following the completion of neoadjuvant treatment.
Arm 2: Placebo with platinum-based chemotherapy
Patients will receive placebo in combination with platinum-based chemotherapy every 3 weeks for up to 4 cycles prior to surgery, followed by placebo monotherapy every 4 weeks for up to 12 cycles after surgery unless disease is deemed unresectable, disease recurrence, or unacceptable toxicity
The platinum-based chemotherapy will be based on tumour histology and Investigator discretion:
* cisplatin with pemetrexed
* carboplatin with pemetrexed
* carboplatin with paclitaxel
* cisplatin with gemcitabine (or carboplatin with gemcitabine for patients who have comorbidities or who are unable to tolerate cisplatin per the investigator's judgment)
Placebo
Day 1 of each 3-week cycle for 4 cycles during the neoadjuvant period and Day 1 of each 4-week cycle for 12 cycles during the adjuvant period
Carboplatin
Area under the curve of 5/6 on Day 1 of each 3-week cycle for 4 cycles
Cisplatin
75 mg/m2 on Day 1 of each 3-week cycle, for 4 cycles
Pemetrexed
500 mg/m2 on Day 1 of each 3-week cycle for 4 cycles.
Paclitaxel
200mg/m2 on Day 1 of each 3-week cycle for 4 cycles.
Gemcitabine
1250 mg/m2 on Day 1 and Day 8 of each 3-week cycle, for 4 cycles.
Surgery
Expected within 40 days from the last dose of Investigational Product following the completion of neoadjuvant treatment.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Durvalumab
1500mg on Day 1 of each 3-week cycle for 4 cycles during the neoadjuvant period and 1500mg on Day 1 of each 4-week cycle for 12 cycles during the adjuvant period
Placebo
Day 1 of each 3-week cycle for 4 cycles during the neoadjuvant period and Day 1 of each 4-week cycle for 12 cycles during the adjuvant period
Carboplatin
Area under the curve of 5/6 on Day 1 of each 3-week cycle for 4 cycles
Cisplatin
75 mg/m2 on Day 1 of each 3-week cycle, for 4 cycles
Pemetrexed
500 mg/m2 on Day 1 of each 3-week cycle for 4 cycles.
Paclitaxel
200mg/m2 on Day 1 of each 3-week cycle for 4 cycles.
Gemcitabine
1250 mg/m2 on Day 1 and Day 8 of each 3-week cycle, for 4 cycles.
Surgery
Expected within 40 days from the last dose of Investigational Product following the completion of neoadjuvant treatment.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Newly diagnosed and previously untreated patients with histologically or cytologically documented NSCLC with resectable (Stage IIA to select \[ie, N2\] Stage IIIB) disease
* World Health Organization (WHO)/ECOG PS of 0 or 1 at enrollment
* At least 1 lesion, not previously irradiated, that qualifies as a RECIST 1.1 Target Lesion (TL) at baseline
* No prior exposure to immune-mediated therapy including, but not limited to, other anti-CTLA-4, anti-PD-1, anti-PD-L1, and anti-PD-L2 antibodies, excluding therapeutic anticancer vaccines
* Adequate organ and marrow function
* Confirmation of a patient's tumour PD-L1 status
* Provision of sufficient tumour biopsy sample for evaluation and confirmation of EGFR and ALK status
* Planned surgery must comprise lobectomy, sleeve resection, or bilobectomy
Exclusion Criteria
* Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease, diverticulitis, systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome)
* History of another primary malignancy
* History of active primary immunodeficiency
* Active infection including tuberculosis hepatitis B and C, or human immunodeficiency virus
* Deemed unresectable NSCLC by multidisciplinary evaluation
* Patients who have pre-operative radiotherapy treatment as part of their care plan
* Patients who have brain metastases or spinal cord compression
* Stage IIIB N3 and Stages IIIC, IVA, and IVB NSCLC
* Known allergy or hypersensitivity to any of the study drugs or excipients
* Existence of more than one primary tumour such as mixed small cell and NSCLC histology
* Patients whose planned surgery at enrollment includes any of the following procedures: pneumonectomy, segmentectomies, or wedge resections
* Patients with a documented test result confirming the presence of EGFRm or ALK translocation
18 Years
120 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
John Heymach, MD
Role: PRINCIPAL_INVESTIGATOR
UT MD Anderson Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Aurora, Colorado, United States
Research Site
Boca Raton, Florida, United States
Research Site
Phoenix, Arizona, United States
Research Site
Duarte, California, United States
Research Site
Orange, California, United States
Research Site
Jacksonville, Florida, United States
Research Site
Chicago, Illinois, United States
Research Site
Wichita, Kansas, United States
Research Site
Ashland, Kentucky, United States
Research Site
Lexington, Kentucky, United States
Research Site
Silver Spring, Maryland, United States
Research Site
Towson, Maryland, United States
Research Site
Duluth, Minnesota, United States
Research Site
Minneapolis, Minnesota, United States
Research Site
Morristown, New Jersey, United States
Research Site
New York, New York, United States
Research Site
New York, New York, United States
Research Site
Shirley, New York, United States
Research Site
Durham, North Carolina, United States
Research Site
Bend, Oregon, United States
Research Site
Medford, Oregon, United States
Research Site
Pittsburgh, Pennsylvania, United States
Research Site
Charleston, South Carolina, United States
Research Site
Charleston, South Carolina, United States
Research Site
Austin, Texas, United States
Research Site
Fort Worth, Texas, United States
Research Site
Houston, Texas, United States
Research Site
Houston, Texas, United States
Research Site
Fairfax, Virginia, United States
Research Site
Kirkland, Washington, United States
Research Site
Seattle, Washington, United States
Research Site
Buenos Aires, , Argentina
Research Site
CABA, , Argentina
Research Site
CABA, , Argentina
Research Site
La Plata, , Argentina
Research Site
Pergamino, , Argentina
Research Site
Rosario, , Argentina
Research Site
San Salvador de Jujuy, , Argentina
Research Site
Viedma, , Argentina
Research Site
Graz, , Austria
Research Site
Innsbruck, , Austria
Research Site
Rankweil, , Austria
Research Site
Vienna, , Austria
Research Site
Vienna, , Austria
Research Site
Ghent, , Belgium
Research Site
Liège, , Belgium
Research Site
Mons, , Belgium
Research Site
Barretos, , Brazil
Research Site
Belo Horizonte, , Brazil
Research Site
Campinas, , Brazil
Research Site
Curitiba, , Brazil
Research Site
Florianópolis, , Brazil
Research Site
Natal, , Brazil
Research Site
Porto Alegre, , Brazil
Research Site
Santa Maria, , Brazil
Research Site
São José do Rio Preto, , Brazil
Research Site
São Paulo, , Brazil
Research Site
São Paulo, , Brazil
Research Site
Teresina, , Brazil
Research Site
Vitória, , Brazil
Research Site
Plovdiv, , Bulgaria
Research Site
Sofia, , Bulgaria
Research Site
Sofia, , Bulgaria
Research Site
Sofia, , Bulgaria
Research Site
Edmonton, Alberta, Canada
Research Site
Kitchener, Ontario, Canada
Research Site
Lévis, Quebec, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Québec, Quebec, Canada
Research Site
Saskatoon, Saskatchewan, Canada
Research Site
Santiago, , Chile
Research Site
Santiago, , Chile
Research Site
Temuco, , Chile
Research Site
Viña del Mar, , Chile
Research Site
Beijing, , China
Research Site
Beijing, , China
Research Site
Beijing, , China
Research Site
Beijing, , China
Research Site
Changsha, , China
Research Site
Changsha, , China
Research Site
Changzhou, , China
Research Site
Chengdu, , China
Research Site
Guangzhou, , China
Research Site
Guangzhou, , China
Research Site
Guiyang, , China
Research Site
Hangzhou, , China
Research Site
Hangzhou, , China
Research Site
Hangzhou, , China
Research Site
Hangzhou, , China
Research Site
Hefei, , China
Research Site
Kunming, , China
Research Site
Linhai, , China
Research Site
Nanchang, , China
Research Site
Ningbo, , China
Research Site
Shanghai, , China
Research Site
Shanghai, , China
Research Site
Shenyang, , China
Research Site
Shenyang, , China
Research Site
Shenzhen, , China
Research Site
Shenzhen, , China
Research Site
Tianjin, , China
Research Site
Ürümqi, , China
Research Site
Wuhan, , China
Research Site
Wuhan, , China
Research Site
Xiamen, , China
Research Site
Xintai, , China
Research Site
Yangzhou, , China
Research Site
Zhengzhou, , China
Research Site
San José, , Costa Rica
Research Site
San José, , Costa Rica
Research Site
Avignon, , France
Research Site
Lyon, , France
Research Site
Nice, , France
Research Site
Toulon, , France
Research Site
Vantoux, , France
Research Site
Bielefeld, , Germany
Research Site
Cologne, , Germany
Research Site
Frankfurt am Main, , Germany
Research Site
Immenstadt im Allgäu, , Germany
Research Site
Budapest, , Hungary
Research Site
Gyöngyös - Mátraháza, , Hungary
Research Site
Győr, , Hungary
Research Site
Székesfehérvár, , Hungary
Research Site
Törökbálint, , Hungary
Research Site
Ahmedabad, , India
Research Site
Gurgaon, , India
Research Site
Gurgaon, , India
Research Site
Kolkata, , India
Research Site
Manipal, , India
Research Site
Mumbai, , India
Research Site
Mumbai, , India
Research Site
Mysuru, , India
Research Site
Namakkal, , India
Research Site
Nashik, , India
Research Site
New Delhi, , India
Research Site
New Delhi, , India
Research Site
Thāne, , India
Research Site
Visakhapatnam, , India
Research Site
Ancona, , Italy
Research Site
Bari, , Italy
Research Site
Bergamo, , Italy
Research Site
Florence, , Italy
Research Site
Milan, , Italy
Research Site
Monza, , Italy
Research Site
Padua, , Italy
Research Site
Roma, , Italy
Research Site
Verona, , Italy
Research Site
Habikino-shi, , Japan
Research Site
Himeji-shi, , Japan
Research Site
Hiroshima, , Japan
Research Site
Hiroshima, , Japan
Research Site
Iwakuni-shi, , Japan
Research Site
Kitaadachi-gun, , Japan
Research Site
Kitakyushu-shi, , Japan
Research Site
Kurashiki Shi, , Japan
Research Site
Nagoya, , Japan
Research Site
Niigata, , Japan
Research Site
Okayama, , Japan
Research Site
Osakasayama-shi, , Japan
Research Site
Toyoake-shi, , Japan
Research Site
Wakayama, , Japan
Research Site
Aguascalientes, , Mexico
Research Site
Chihuahua City, , Mexico
Research Site
Guadalajara, , Mexico
Research Site
México, , Mexico
Research Site
México, , Mexico
Research Site
Monterrey, , Mexico
Research Site
Monterrey, , Mexico
Research Site
Pachuca, , Mexico
Research Site
Arnhem, , Netherlands
Research Site
Nijmegen, , Netherlands
Research Site
Bellavista, , Peru
Research Site
Lima, , Peru
Research Site
Lima, , Peru
Research Site
Lima, , Peru
Research Site
Lima, , Peru
Research Site
Davao City, , Philippines
Research Site
Iloilo City, , Philippines
Research Site
Makati, , Philippines
Research Site
Quezon City, , Philippines
Research Site
Bialystok, , Poland
Research Site
Olsztyn, , Poland
Research Site
Warsaw, , Poland
Research Site
Warsaw, , Poland
Research Site
Suceava, , Romania
Research Site
Kazan', , Russia
Research Site
Krasnoyarsk, , Russia
Research Site
Moscow, , Russia
Research Site
Moscow, , Russia
Research Site
Moscow, , Russia
Research Site
Moscow, , Russia
Research Site
Nizhny Novgorod, , Russia
Research Site
Obninsk, , Russia
Research Site
Rostov-on-Don, , Russia
Research Site
Saint Petersburg, , Russia
Research Site
Tomsk, , Russia
Research Site
Yaroslavl, , Russia
Research Site
Busan, , South Korea
Research Site
Cheongju-si, , South Korea
Research Site
Seongnam-si, , South Korea
Research Site
Seoul, , South Korea
Research Site
Seoul, , South Korea
Research Site
Suwon, , South Korea
Research Site
Suwon, , South Korea
Research Site
Alicante, , Spain
Research Site
Barcelona, , Spain
Research Site
Donostia / San Sebastian, , Spain
Research Site
Madrid, , Spain
Research Site
Málaga, , Spain
Research Site
Oviedo, , Spain
Research Site
Pamplona, , Spain
Research Site
Santiago de Compostela (A Coruña), , Spain
Research Site
Changhua, , Taiwan
Research Site
Taichung, , Taiwan
Research Site
Taichung, , Taiwan
Research Site
Tainan City, , Taiwan
Research Site
Tainan City, , Taiwan
Research Site
Taipei, , Taiwan
Research Site
Taipei, , Taiwan
Research Site
Taipei, , Taiwan
Research Site
Bangkok, , Thailand
Research Site
Bangkok, , Thailand
Research Site
Chiang Mai, , Thailand
Research Site
Chiang Rai, , Thailand
Research Site
Khon Kaen, , Thailand
Research Site
Lampang, , Thailand
Research Site
Hanoi, , Vietnam
Research Site
Ho Chi Minh City, , Vietnam
Research Site
Ho Chi Minh City, , Vietnam
Research Site
Ho Chi Minh City, , Vietnam
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Mitsudomi T, Heymach JV, Reck M, Taube JM, Gao S, Horio Y, You J, Li G, Van Luong D, Saeteng S, Tanaka F, Watzka SB, Urban L, Szalai Z, Akamatsu H, Kang JH, Orlandi FJ, Mukhametshina GZ, Pircher A, Teixeira CHA, Aperghis M, Doherty GJ, Doake R, Fouad TM, Harpole D. Surgical Outcomes With Neoadjuvant Durvalumab Plus Chemotherapy Followed by Adjuvant Durvalumab in Resectable NSCLC. J Thorac Oncol. 2025 Jun 20:S1556-0864(25)00780-4. doi: 10.1016/j.jtho.2025.06.015. Online ahead of print.
Heymach JV, Harpole D, Mitsudomi T, Taube JM, Galffy G, Hochmair M, Winder T, Zukov R, Garbaos G, Gao S, Kuroda H, Ostoros G, Tran TV, You J, Lee KY, Antonuzzo L, Papai-Szekely Z, Akamatsu H, Biswas B, Spira A, Crawford J, Le HT, Aperghis M, Doherty GJ, Mann H, Fouad TM, Reck M; AEGEAN Investigators. Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer. N Engl J Med. 2023 Nov 2;389(18):1672-1684. doi: 10.1056/NEJMoa2304875. Epub 2023 Oct 23.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2018-002997-29
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
D9106C00001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.